
## Maria C Carrillo

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8644517/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Agingâ€Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimer's and Dementia, 2011, 7, 263-269.	0.8	12,681
2	NIAâ€AA Research Framework: Toward a biological definition of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 535-562.	0.8	5,861
3	Preclinical Alzheimer's disease: Definition, natural history, and diagnostic criteria. Alzheimer's and Dementia, 2016, 12, 292-323.	0.8	1,318
4	Summary of the evidence on modifiable risk factors for cognitive decline and dementia: A populationâ€based perspective. Alzheimer's and Dementia, 2015, 11, 718-726.	0.8	1,187
5	Vascular contributions to cognitive impairment and dementia including Alzheimer's disease. Alzheimer's and Dementia, 2015, 11, 710-717.	0.8	461
6	Consensus classification of posterior cortical atrophy. Alzheimer's and Dementia, 2017, 13, 870-884.	0.8	423
7	Research priorities to reduce the global burden of dementia by 2025. Lancet Neurology, The, 2016, 15, 1285-1294.	10.2	284
8	Worldâ€Wide FINGERS Network: A global approach to risk reduction and prevention of dementia. Alzheimer's and Dementia, 2020, 16, 1078-1094.	0.8	257
9	Down syndrome and Alzheimer's disease: Common pathways, commonÂgoals. Alzheimer's and Dementia, 2015, 11, 700-709.	0.8	218
10	Guidelines for the standardization of preanalytic variables for bloodâ€based biomarker studies in Alzheimer's disease research. Alzheimer's and Dementia, 2015, 11, 549-560.	0.8	205
11	Sex biology contributions to vulnerability to Alzheimer's disease: A think tank convened by the Women's Alzheimer's Research Initiative. Alzheimer's and Dementia, 2016, 12, 1186-1196.	0.8	180
12	The roles of inflammation and immune mechanisms inÂAlzheimer'sÂdisease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2016, 2, 99-109.	3.7	161
13	Developing novel bloodâ€based biomarkers for Alzheimer's disease. Alzheimer's and Dementia, 2014, 10, 109-114.	0.8	138
14	Tau: From research to clinical development. Alzheimer's and Dementia, 2016, 12, 1033-1039.	0.8	117
15	Global standardization measurement of cerebral spinal fluid for Alzheimer's disease: An update from the Alzheimer's Association Global Biomarkers Consortium. Alzheimer's and Dementia, 2013, 9, 137-140.	0.8	105
16	Can we prevent Alzheimer's disease? Secondary "prevention―trials in Alzheimer's disease. Alzheimer's and Dementia, 2013, 9, 123.	0.8	100
17	Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2017, 3, 83-91.	3.7	94
18	Retinal imaging in Alzheimer's and neurodegenerative diseases. Alzheimer's and Dementia, 2021, 17, 103-111.	0.8	89

MARIA C CARRILLO

#	Article	IF	CITATIONS
19	Alzheimer's disease: The next frontier—Special Report 2017. Alzheimer's and Dementia, 2017, 13, 374-380.	0.8	88
20	Worldwide Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2012, 8, 337-342.	0.8	84
21	Revolutionizing Alzheimer's disease and clinical trials through biomarkers. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 412-419.	2.4	80
22	CAP—advancing the evaluation of preclinical Alzheimer disease treatments. Nature Reviews Neurology, 2016, 12, 56-61.	10.1	80
23	The case for low-level BACE1 inhibition for the prevention of Alzheimer disease. Nature Reviews Neurology, 2021, 17, 703-714.	10.1	65
24	2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. , 2014, 10, S430-S452.		64
25	Measures of resting state EEG rhythms for clinical trials in Alzheimer's disease: Recommendations of an expert panel. Alzheimer's and Dementia, 2021, 17, 1528-1553.	0.8	64
26	Alzheimer's Disease prevalence, costs, and prevention for military personnel and veterans. Alzheimer's and Dementia, 2014, 10, S105-10.	0.8	56
27	Association Between Ambient Air Pollution and Amyloid Positron Emission Tomography Positivity in Older Adults With Cognitive Impairment. JAMA Neurology, 2021, 78, 197.	9.0	54
28	Further understanding the connection between Alzheimer's disease and Down syndrome. Alzheimer's and Dementia, 2020, 16, 1065-1077.	0.8	52
29	Round robin test on quantification of amyloidâ€Î² 1–42 in cerebrospinal fluid by mass spectrometry. Alzheimer's and Dementia, 2016, 12, 55-59.	0.8	46
30	The Worldwide Alzheimer's Disease Neuroimaging Initiative: An update. Alzheimer's and Dementia, 2015, 11, 850-859.	0.8	43
31	Revisiting the framework of the National Institute on Agingâ€Alzheimer's Association diagnostic criteria. Alzheimer's and Dementia, 2013, 9, 594-601.	0.8	42
32	Ethical challenges in preclinical Alzheimer's disease observational studies and trials: Results of the Barcelona summit. Alzheimer's and Dementia, 2016, 12, 614-622.	0.8	42
33	Challenges, solutions, and recommendations for Alzheimer's disease combination therapy. , 2016, 12, 623-630.		39
34	The biomarker-based diagnosis of Alzheimer's disease. 1—ethical and societal issues. Neurobiology of Aging, 2017, 52, 132-140.	3.1	39
35	Randomized controlled trials in mild cognitive impairment. Neurology, 2017, 88, 1751-1758.	1.1	35
36	Exploring the nexus of Alzheimer's disease and related dementias with cancer and cancer therapies: A convening of the Alzheimer's Association & Alzheimer's Drug Discovery Foundation. Alzheimer's and Dementia, 2017, 13, 267-273.	0.8	35

MARIA C CARRILLO

#	Article	IF	CITATIONS
37	Evolving Evidence for the Value of Neuroimaging Methods and Biological Markers in Subjects Categorized with Subjective Cognitive Decline. Journal of Alzheimer's Disease, 2015, 48, S171-S191.	2.6	34
38	The Longitudinal Earlyâ€onset Alzheimer's Disease Study (LEADS): Framework and methodology. Alzheimer's and Dementia, 2021, 17, 2043-2055.	0.8	34
39	Collaboration for Alzheimer's Prevention: Principles to guide data and sample sharing in preclinical Alzheimer's disease trials. Alzheimer's and Dementia, 2016, 12, 631-632.	0.8	26
40	Testing and disclosures related to amyloid imaging and Alzheimer's disease: Common questions and fact sheet summary. Alzheimer's and Dementia, 2016, 12, 510-515.	0.8	23
41	Militaryâ€related risk factors for dementia. Alzheimer's and Dementia, 2018, 14, 1651-1662.	0.8	18
42	rPOP: Robust PET-only processing of community acquired heterogeneous amyloid-PET data. NeuroImage, 2022, 246, 118775.	4.2	17
43	Alzheimer's disease research in the context of the national plan to address Alzheimer's disease. Molecular Aspects of Medicine, 2015, 43-44, 16-24.	6.4	14
44	Working Group Recommendations for the Practice of Teleneuropsychology in Latin America. Archives of Clinical Neuropsychology, 2022, 37, 553-567.	0.5	12
45	Perspective: The Alzheimer's Disease Neuroimaging Initiative and the role and contributions of the Private Partner Scientific Board (PPSB). Alzheimer's and Dementia, 2015, 11, 840-849.	0.8	10
46	Alzheimer's disease publicâ€private partnerships: Update 2014. Alzheimer's and Dementia, 2014, 10, 873-880.	0.8	9
47	EEG measures for clinical research in major vascular cognitive impairment: recommendations by an expert panel. Neurobiology of Aging, 2021, 103, 78-97.	3.1	9
48	Alzheimer's disease research in Ibero America. Alzheimer's and Dementia, 2016, 12, 749-754.	0.8	7
49	National Institute on Aging – Alzheimer's Association Research Framework lays the groundwork for deeper understanding of Alzheimer's disease. Alzheimer's and Dementia, 2018, 14, 261-262.	0.8	7
50	Justifying reimbursement for Alzheimer's diagnostics and treatments: Seeking alignment on evidence. , 2014, 10, 503-508.		6
51	Is cognitive decline measurable in preclinical Alzheimer's disease?. Alzheimer's and Dementia, 2017, 13, 322-323.	0.8	6
52	Potential roles of digital technologies in clinical trials. Alzheimer's and Dementia, 2017, 13, 1075-1076.	0.8	6
53	Patient and Caregiver Assessment of the Benefits From the Clinical Use of Amyloid PET Imaging. Alzheimer Disease and Associated Disorders, 2018, 32, 35-42.	1.3	5
54	The pathway to secondary prevention of Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2020, 6, e12069.	3.7	5

#	Article	IF	Citations
55	Commentary: Global Alzheimer's disease and Alzheimer's disease related dementia research funding organizations support and engage the research community throughout the COVIDâ€19 pandemic. Alzheimer's and Dementia, 2022, 18, 1067-1070.	0.8	4
56	Alzheimer's disease public-private partnerships: Update 2017. , 2018, 14, 522-531.		3
57	How Should Cognitive Impairment Be Recognized?. Journal of the American Medical Directors Association, 2015, 16, 813-814.	2.5	2
58	Considering new treatment paradigms for neuropsychiatric symptomsÂofÂAlzheimer's disease. Alzheimer's and Dementia, 2016, 12, 1031-1032.	0.8	2
59	Clinical meaningfulness addressed at Alzheimer's Association Research Roundtable. Alzheimer's and Dementia, 2020, 16, 814-814.	0.8	2
60	Letter to the Editor re: Nexus of Cancer & amp; Alzheimer's. Alzheimer's and Dementia, 2017, 13, 722-722.	0.8	1
61	Combination therapy for Alzheimer's disease: Are we ready?. Alzheimer's and Dementia, 2018, 14, 1232-1233.	0.8	1
62	Lifestyle and its Potential to Preserve Cognitive Function and Reduce the Risk of Dementia. US Neurology, 2018, 14, 11.	0.2	1
63	Perspective from the Alzheimer's Association: Neuroimaging Professional Interest Area of ISTAART continues impact on the field. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2016, 5, 1-2.	2.4	0
64	AAIC Satellite Symposium explores Alzheimer's disease research in South Asia. , 2019, 15, 726-727.		0
65	Targeting Alzheimer's Disease in the Preclinical Stage. , 2019, 15, 602-603.		0

MARIA C CARRILLO

0.8

0

66 Scientific Advising and Reviewing: On strengthening the bond between the Alzheimer's Association and the scientific community. Alzheimer's and Dementia, 2020, 16, 1095-1098.